Michael Loberg
Plus aucun poste en cours
Fortune : 690 790 $ au 31/05/2024
Profil
Michael D.
Loberg served as President & CEO of NetMed, Inc. and President, CEO & Director of NitroMed, Inc. He was also a Director of ArQule, Inc., Independent Director of Inotek Pharmaceuticals Corp., and Director of AMAG Pharmaceuticals, Inc. Loberg was previously Director & VP of E.R.
Squibb & Sons LLC and President-Oncology & Immunology of Bristol Myers Squibb Co. He started his career as an Associate Professor at the University of Maryland.
Loberg holds a doctorate from Washington University in St. Louis and an undergraduate degree from Trinity College (Connecticut).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IGM BIOSCIENCES, INC.
0,25% | 29/09/2023 | 82 928 ( 0,25% ) | 690 790 $ | 31/05/2024 |
Anciens postes connus de Michael Loberg
| Sociétés | Poste | Fin |
|---|---|---|
| IGM BIOSCIENCES, INC. | Président | 03/10/2023 |
| ARQULE, INC. | Directeur/Membre du Conseil | 01/01/2020 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Président | 03/06/2011 |
| AMAG PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 15/05/2009 |
| NETMED, INC. | President | 01/03/2006 |
Formation de Michael Loberg
| Trinity College (Connecticut) | Undergraduate Degree |
| Washington University in St. Louis | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NETMED, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| IGM BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Kereos, Inc.
 Kereos, Inc. Pharmaceuticals: MajorHealth Technology Kereos, Inc. develops and manufactures biotechnology products. The firm focuses on nanodroplet technology that allows delivery of a range of drug compounds to a target in the body for the treatment of diseases. The company was founded by Samuel A. Wickline and Gregory M. Lanza in 1999 and is headquartered in St. Louis, MO. | Health Technology |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
| E. R. Squibb & Sons LLC | |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
NitroMed, Inc.
 NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Health Technology |
| E.R. Squibb & Sons Research & Development |
